selgantolimod: Clinical Trials

4 trials of selgantolimod, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1

Follow selgantolimod: new trials by email Literature Review of selgantolimod trials Research Report on selgantolimod

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Selgantolimod, Placebo - Hepatitis B, HIV Infections
Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)292023-05-012026-11-17
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
Tenofovir Alafenamide, VIR-2218, Nivolumab - Chronic Hepatitis B
Phase 2CompletedGilead Sciences1032021-08-142025-07-24
Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment
Placebo, Selgantolimod, TAF - Chronic Hepatitis B
Phase 2CompletedGilead Sciences672018-08-282022-05-10
Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy - Chronic Hepatitis B
Phase 2CompletedGilead Sciences482018-04-062021-08-19

Conditions studied

Hepatitis B, Chronic (3)  ·  HIV Infections (1)  ·  Hepatitis B (1)

Sponsors

Gilead Sciences (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

New Zealand (2)  ·  South Korea (2)  ·  Thailand (2)  ·  United States (2)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  Denmark (1)  ·  Hong Kong (1)  ·  Peru (1)  ·  Singapore (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Results publications

PMID 38133554